Differences in episode-based care costs for multidetector computed tomographic coronary angiography versus myocardial perfusion imaging for the diagnosis of coronary artery disease

Journal of Medical Economics

Volumn 11, Issue 2, 2008, Pages 327-340

  Min, James K ^a   Robinson, Matthew ^b   Shaw, Leslee J ^c   Lin, Fay ^a   Legorreta, Antonio P ^b,d   Gilmore, Amanda ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Health Benchmarks Inc   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiography; Computed tomography; Coronary disease; Cost

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE;

ADULT; ARTICLE; COMORBIDITY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIAGNOSTIC TEST; ECONOMIC EVALUATION; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HEART CATHETERIZATION; HEART SCINTISCANNING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MYOCARDIAL PERFUSION SCINTIGRAPHY; RETROSPECTIVE STUDY; TRANSLUMINAL CORONARY ANGIOPLASTY;

COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; DIAGNOSTIC IMAGING; EPISODE OF CARE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERFUSION IMAGING; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 50649117019     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990802134291     Document Type: Article

References (22)

1. Klocke FJ, Baird MG, Lorrell BH et al. ACC/AHA/ASNC Guidelines for the Clinical Use of Cardiac Radionuclide Imaging: Executive Summary - A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003; 108: 1404-1418.
2. Berman DS, Hachamovitch R, Kiat H et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Journal of the American College of Cardiology 1995; 26: 639-647.
3. Hachamovitch R, Shaw L, Berman DS. Methodological consideration in the assessment of noninvasive testing using outcomes research: pitfalls and limitations. Progress in Cardiovascular Diseases 2000; 43: 215-230.
4. Hamon M, Giuseppe GB, Malagutti P et al. Diagnostic performance of multislice spiral computed tomograpny or coronary arteries as compared with conventional invasive coronary angiography: a meta-analysis. Journal of the American College of Cardiology 2006; 48: 1896-1910.
5. Min JK, Shaw LJ, Devereux RB et al. Prognostic value of multidetector coronary CT angiography for prediction of all-cause mortality. Journal of the American College of Cardiology 2007; 50(12): 1161-1170.
6. Pundziute G, Schuijf JD, Wouter JJ et al. Prognostic value of multislice computed tomography coronary angiography in patients with known or suspected coronary artery disease. Journal of the American College of Cardiology 2007; 49: 62-70.
7. Levit KR, Lazensby HC, Braden BR. National health expenditures. Health Affairs (Project Hope) 1996; 17: 35-51.
8. Burner ST, Waldo DR, McKusick DR. National health care expenditures. Health Care Financing Review 1996; 14: 1-30.
9. http://www.americanheart.org/presenter.jhtml?identifier=3000996.
10. Ginzberg E. Health Services Research. Cambridge, MA: Harvard University Press, 1991.
11. Fuchs U. The Future of Health Policy. Cambridge, MA: Harvard University Press, 1993.
12. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987; 40(5): 373-383.
13. Needham DM, Scales DC, Laupacis A, Pronovost PJ. A systematic review of the Charlson Comorbidity Index using Canadian administrative databases: a perspective on risk adjustment in critical care research. Journal of Critical Care 2005; 20(1): 12-19.
14. de Groot V, Beckerman H, Lankhorts GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. Journal of Clinical Epidemiology 2003; 56(3): 221-229.
15. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. International Journal of Epidemiology 2000; 29(5): 891-898.
16. Forthman MT, Dove HG, Wooster LD. Episode treatment groups (ETGs): a patient classification for measuring outcomes performance by episode of illness. Topics in Health Information Management 2000; 21(2): 51-61.
17. Dang DK, Pont JM, Portmoy MA. Episode treatment groups: an illness classification and episode building system - Part II. Medical Interface 1996; 9(4): 122-128.
18. Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system - Part I. Medical Interface 1996; 9(3): 118-122.
19. Ray WA, Stein CM, Hall K et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 2002; 359(9301): 118-123.
20. Carey K. A multilevel modelling approach to analysis of patient costs under managed care. Health Economics 2000; 9: 435-446.
21. Raboud J, Breslow NE. Efficiency gains from the addition of controls to matched sets in cohort studies. Statistics in Medicine, 1989; 8(8): 977-985.
22. Pohle K, Achenbach S, Macneil B et al. Characterization of non-calcified coronary atherosclerotic plaque by multi-detector row CT: comparison to IVUS. Atherosclerosis 2007; 190(1): 174-180.